FDA HAS APPROVED FILSPARI™ (SPARSENTAN), THE FIRST-IN-CLASS NON-IMMUNOSUPPRESSIVE THERAPY FOR THE REDUCTION OF PROTEINURIA IN IgA NEPHROPATHY
FDA HAS APPROVED FILSPARI™ (SPARSENTAN), THE FIRST-IN-CLASS NON-IMMUNOSUPPRESSIVE THERAPY FOR THE REDUCTION OF PROTEINURIA IN IgA NEPHROPATHY